Abstract 177P
Background
Chemotherapy with Taxanes is often the preferred clinical treatment for breast cancer patients. Unfortunately, these agents become increasingly ineffective during treatment. Pro-tumoral M2 tumor-associated macrophages (TAMs) are the most abundant immune cells in the breast tumor microenvironment. In a first-in-human study (NCT00358163, NCT00731861), Vatalanib (PTK787/ZK) was well tolerated alone or in combination with paclitaxel. Here, we explored the pre-clinical efficacy of combination of Vatalanib and paclitaxel in TAM-induced chemoresistance in breast cancer.
Methods
We reported translational analysis of expression of BIRC5 and its correlation with Overall Survival (OS) in breast cancer patients. Western blotting, immunofluorescence imaging, and Real-time PCR analysis were used to determine survivin (BIRC5), pVEGFR2 and STAT3 in vitro. 4T1 cells and RAW 264.7 cells were injected in BALB/c mice to generate syngeneic chemoresistant breast tumor model in vivo.
Results
We measured survivin (BIRC5) upregulation in breast tumor (n=288) as compared to normal breast tissue (n=211) using TCGA datasets. Further, retrospective study confirmed that an increase in BIRC5 expression decreases Overall Survival (OS) in breast cancer. Using the invitro co-culture system, we validated that the macrophage secreted VEGF-A contributes to chemoresistance against paclitaxel. Mechanistically, VEGFA, by binding to VEGFR2, activated the transcription factor STAT3 leading to increased expression of anti-apoptotic protein survivin in breast cancer cells. Therapeutically, the TAM-induced STAT3/survivin signaling could be abrogated by Vatalanib thereby reversing the chemoresistance. The data shows that the combination of paclitaxel with Vatalanib exhibit reduced M2-TAMs, indicating that the combination effectively altered tumor microenvironment in the in vivo 4T1 breast tumor model.
Conclusions
Together, our study revealed the role of TAMs in conferring paclitaxel resistance in breast cancer. Combinatorial VEGFR2 blockade and paclitaxel chemotherapy decreased TAM population and showed better prognostic outcomes in breast cancer.
Legal entity responsible for the study
B. Deswal, S. Kapoor.
Funding
Department of Biotechnology, Government of India; Department of Science and Technology, Government of India.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
14P - Integrated modelling of T cell repertoires to identify clonotype signatures of ICI response
Presenter: Juan Luis Melero
Session: Poster Display
16P - Exosomal PD-L1 and lactate predict clinical outcomes of PD-1 blockade combined with chemotherapy in advanced-stage gastric and gastroesophageal junction adenocarcinoma
Presenter: Yongshun Chen
Session: Poster Display
17P - Spatial Characteristics Associated with the Chemo and Immuno-treatment Response of Gastric Cancer Revealed by Multi-omics Analysis
Presenter: Gang Che
Session: Poster Display
18P - Association of DNA methylation profiles with pathologic complete response in early triple negative breast cancer patients receiving neoadjuvant chemoimmunotherapy
Presenter: Angelika Starzer
Session: Poster Display
19P - The prognostic value of soluble CD73 in advanced triple-negative breast cancer: an exploratory analysis of the SYNERGY trial
Presenter: Denis Zoë
Session: Poster Display
21P - Mass cytometry reveals a population of exhausted CD8+ T cells associated with durvalumab/tremelimumab/vinorelbine efficacy in advanced cervical cancer (iMOVIE).
Presenter: Alexandre Bertucci
Session: Poster Display
22P - Predictive value of Tertiary Lymphoid Structure in patients with mismatch repair deficient advanced/ recurrent endometrial cancer treated with Dostarlimab.
Presenter: Maria Kfoury
Session: Poster Display
23P - Circulating immune cells and activity of immune checkpoint inhibitors in metastatic renal cell carcinoma
Presenter: Ronan Flippot
Session: Poster Display
24P - Chromosome 3p-related gene alterations (GA) as biomarkers for immunocombinations in metastatic renal cell carcinoma (mRCC): a hypothesis-generating analysis
Presenter: Matteo Rosellini
Session: Poster Display